KZR Kezar Life Sciences Inc.

3.89
+0.27  (+7%)
Previous Close 3.62
Open 3.61
Price To Book 0.79
Market Cap 74,445,439
Shares 19,137,645
Volume 12,142
Short Ratio
Av. Daily Volume 78,690

NewsSee all news

  1. Kezar Life Sciences Announces Presentations at Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b updated data due 4Q 2019. Phase 2 portion has been initiated.
KZR-616
Lupus
Phase 1 initiation announced March 6, 2019.
KZR-616
Healthy volunteers
Phase 2 trial has been initiated.
KZR-616
Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP)
Phase 2 trial has been initiated.
KZR-616
Dermatomyositis and polymyositis

Latest News

  1. Kezar Life Sciences Announces Presentations at Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet